|
Press Releases
February 9, 2010
Provectus' PV-10 and Radiotherapy Featured in Peer Reviewed Journal
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announces the publication of an article, entitled
"A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr.
Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed
journal, Melanoma Research (20(1):48-51, February 2010).
Read the complete article here.
January 7, 2010
Provectus Pharmaceuticals Reports to Shareholders on 2009 Accomplishments and Clinical Development Plans
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
reports on its 2009 clinical and corporate accomplishments, as well as 2010 clinical development plans, in a letter to shareholders
from Craig Dees, Ph.D., CEO of Provectus.
Read the complete article here.
December 1, 2009
Provectus Announces Preliminary Phase 2 Data For PH-10 in its Psoriasis and Atopic Dermatitis Trials
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced preliminary data for the company's PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical
trial for Atopic Dermatitis.
Read the complete article here.
November 23, 2009
Interim Phase 2 Survival Data for PV-10 Shows Markedly Longer Overall and Disease Specific Survival for Subjects Responsive to PV-10
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival
data. Survival data for the Phase 1 study of PV-10 for metastatic melanoma continues to show markedly longer overall and disease specific survival for subjects
that were responsive to PV-10 relative to those who did not experience a robust response. Survival data was available through early November 2009.
Read the complete article here.
November 17, 2009
Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of
Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic
Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November
21, 2009 in Berlin, Germany.
Read the complete article here.
October 14, 2009
Provectus Pharmaceuticals Initiates Compassionate Use Program of PV-10 for Non-Visceral Indications in Cancer Patients in U.S.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers,
available for select cancer patients in the United States.
Read the complete article here.
|
